BioWorld

May 28, 2003

View Archived Issues

EPIX In $28M Deal To Develop Contrast Agents With Schering

EPIX Medical Inc. is returning to a familiar partner, Schering AG, to develop contrast agents for use in MRI in a deal that could garner up to $28 million in near-term money for EPIX.(BioWorld Today) Read More

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

Read More

Peninsula In-Licenses Late-Stage Antibiotic From Japanese Firm

Read More

Vitex Offering Brings In $14.4M For Blood Purifying Technology

Read More

Other News To Note

Read More